1. Inhibitory effect of enzyme can effectively inhibit the activities of trypsin, -chymotrypsin, granulocyte elastase and cathepsin, and remove the damage caused by hydrolase in blood to tissue cells;

　　2. Anti-inflammatory effects inhibit the release of inflammatory cytokines and lysosomal enzymes, stabilize the cell membranes of monocytes and neutrophils, and reduce the release of inflammatory mediators;

　　3. Improving microcirculation and tissue perfusion inhibits the generation of myocardial inhibitory factors, reduces the generation of kinidin, stabilizes lysosomal membrane, and improves metabolic abnormalities.

　　Ulinastatin is different from the therapeutic drugs that antagonizes one or several cytokines, and does not bring side effects such as immune suppression, stress ulcer bleeding and osteoporosis like glucocorticoids. As an in vivo anti-inflammatory complementary therapy, ulinastatin is positively correlated with the severity of the disease and the dose to be supplemented. SIRS are regulated by a complex signal network, and single drugs antagonizing a certain cytokine are ineffective. Clinical practice has shown that ulinastatin supplementation with SIRS in vitro successfully blocks and interferes the development of SIRS by inhibiting the inflammatory reactivation-related hydrolases and the over-activation of inflammatory cells! At present, ulinastatin is widely used in the treatment of SAP, CARDIopulmonary resuscitation, severe multiple injuries, compound injuries, burns, sepsis, shock and other critically ill patients.

　　That's all about ulinastatin. Stay tuned for more.